Ethics for end-of-life treatments: Metastatic colorectal cancer is one example

Livio Garattini, Katelijne van de Vooren and Alberto Zaniboni

Health Policy, 2013, vol. 109, issue 1, 97-103

Abstract: The number of biological agents (BAs) registered with an indication related to cancer treatment is flourishing and the cost of these treatments is rising dramatically, making the situation potentially unsustainable for healthcare systems. Here we focus on the examples of bevacizumab (BV) and cetuximab (CX), two BAs approved for metastatic colorectal cancer (mCRC). The first clinical trials show an increase in median overall survival of a few months, though these results could not always be repeated in subsequent studies.

Keywords: Colorectal cancer; Economic evaluation; Health technology assessment; Ethics; Biological agents (search for similar items in EconPapers)
Date: 2013
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0168851012002266
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:109:y:2013:i:1:p:97-103

DOI: 10.1016/j.healthpol.2012.08.017

Access Statistics for this article

Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput

More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu () and ().